Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maida EM, Alexandri N, Smyk A, Nolting A, Keller B, Montalban X, Kubala Havrdova E. Brochet B, et al. Among authors: keller b. Mult Scler. 2023 Dec;29(14):1808-1818. doi: 10.1177/13524585231205962. Epub 2023 Nov 18. Mult Scler. 2023. PMID: 37978852 Free PMC article.
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B. Brochet B, et al. Among authors: keller b. Mult Scler Relat Disord. 2022 Jan;57:103385. doi: 10.1016/j.msard.2021.103385. Epub 2021 Nov 9. Mult Scler Relat Disord. 2022. PMID: 35158476 Free article. Clinical Trial.
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B, Alexandri N, Galazka A. De Stefano N, et al. Among authors: keller b. Mult Scler. 2022 Jan;28(1):111-120. doi: 10.1177/13524585211010294. Epub 2021 May 10. Mult Scler. 2022. PMID: 33969750 Free PMC article.
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
de Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Roy S; MAGNIFY-MS Study Group. de Stefano N, et al. Among authors: keller b. Neurol Neuroimmunol Neuroinflamm. 2022 Jun 14;9(4):e1187. doi: 10.1212/NXI.0000000000001187. Print 2022 Jul. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35701185 Free PMC article.
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, Jack D, Vermersch P. Giovannoni G, et al. Among authors: keller b. Adv Ther. 2021 Sep;38(9):4975-4985. doi: 10.1007/s12325-021-01865-w. Epub 2021 Aug 9. Adv Ther. 2021. PMID: 34370275 Free PMC article. Clinical Trial.
Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Trinka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, Löffler K, Rocha JF, Soares-da-Silva P. Trinka E, et al. Among authors: keller b. Epilepsia. 2018 Feb;59(2):479-491. doi: 10.1111/epi.13993. Epub 2018 Jan 25. Epilepsia. 2018. PMID: 29369348 Clinical Trial.
COVID-19 progression and convalescence in common variable immunodeficiency patients show dysregulated adaptive immune responses and persistent type I interferon and inflammasome activation.
Rodríguez-Ubreva J, Calafell-Segura J, Calvillo CL, Keller B, Ciudad L, Handfield LF, de la Calle-Fabregat C, Godoy-Tena G, Andrés-León E, Hoo R, Porter T, Prigmore E, Hofmann M, Decker A, Martín J, Vento-Tormo R, Warnatz K, Ballestar E. Rodríguez-Ubreva J, et al. Among authors: keller b. Nat Commun. 2024 Nov 28;15(1):10344. doi: 10.1038/s41467-024-54732-x. Nat Commun. 2024. PMID: 39609471 Free PMC article.
The role of induction therapy in lung transplantation.
Landino SM, Nawalaniec JT, Hays N, Osho AA, Keller BC, Allan JS, Keshavjee S, Madsen JC, Hachem R. Landino SM, et al. Among authors: keller bc. Am J Transplant. 2024 Nov 16:S1600-6135(24)00695-6. doi: 10.1016/j.ajt.2024.11.011. Online ahead of print. Am J Transplant. 2024. PMID: 39551266 Review.
1,452 results